跳至主要内容
临床试验/NCT02720354
NCT02720354已完成1 期

A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"

Synektik S.A.0 个研究点目标入组 12 人开始时间: 2016年5月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
12
主要终点
Measurement of absorbed radiation dose for all target organs in megabecquerel (the activity of a quantity of radioactive material in which one nucleus decays per second).

研究概览

简要总结

[11C]-dimethyl-diphenyl ammonium ([11C]-DMDPA) - A Phase I, Open-label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First-in-Human Study of a Novel 11C-labeled Tracer for Positron Emission Tomography Myocardial Perfusion Imaging

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •body mass index (BMI) between 18.0 and 30.0 kg/m2
  • •good health
  • •written informed consent

排除标准

  • •subject receiving medication
  • •a blood transfusion in the 4 weeks prior to screening
  • •positive alcohol blood test
  • •Subjects who suffer from claustrophobia
  • •Subjects who have had a clinically significant illness
  • •Subjects exposed to radiation within 12 months prior to screening

研究组 & 干预措施

A single Intravenous bolus injection

Experimental

A single Intravenous bolus injection of 11C[DMDPA]

干预措施: [11C]-DMDPA (Other)

结局指标

主要结局

Measurement of absorbed radiation dose for all target organs in megabecquerel (the activity of a quantity of radioactive material in which one nucleus decays per second).

时间窗: within 80 minutes

次要结局

未报告次要终点

研究者

发起方
Synektik S.A.
申办方类型
Industry
责任方
Sponsor

相似试验